Disease progression and treatment optimization 

The group of diseases termed "cancer" is as heterogeneous as those people affected by it. Just as each person has a unique fingerprint, each individual's cancer has its own molecular profile, which can lead to differing responses to treatment. For example, while a successful cancer drug may have a 30% overall response rate, when used to treat the appropriate molecular subtype it may have a 70% success rate.
The scope of tests offered by Oncotest – Advantest may evaluate the unique biology of each patient’s cancer and predict the likely course of the disease for that individual. In turn, this knowledge makes it possible for physicians and patients to help individualize a treatment plan, which may potentially improve patient outcomes.
The unique molecular data is derived from tests performed on the patient's tumor sample. Educated use of these tests, augmented by the clinical experience of treating physicians, ensures that the fateful intersection between man, disease and treatment be crossed under optimal conditions.